Chemoradiotherapy

Merck to Present Latest Research from Oncology Portfolio at ESMO 2023

Retrieved on: 
月曜日, 10月 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Annual general meeting, Cancer, Cetuximab, UC, Food, MCC, Biomarker, Abstract, IAP, NSCLC, Apoptosis, European Society for Medical Oncology, Cisplatin, OS, Ageing, Safety, Lung cancer, US Foods, Angela Merkel, Patient, FDA, ESMO, Chemoradiotherapy, Skin cancer, Phase, Booth, LA, Neck, Maintenance, Bladder cancer, Lung, Head, Avelumab, Progression-free survival, MET, SCCHN, Pharmaceutical industry, Nightclub, Merck

Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.

Key Points: 
  • Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.
  • Presentations at the meeting encompass new analyses for the standard-of-care medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab).
  • Additional presentations and activities at ESMO highlight the company’s efforts to improve the lives of people with cancer.
  • New analyses and real-world evidence to be presented at ESMO reinforce the role of the JAVELIN Bladder regimen in this setting.

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Retrieved on: 
火曜日, 10月 10, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, NYSE, Abstract, Breast cancer, Brentuximab vedotin, INT, Trastuzumab, RCC, Survival, Endometrial cancer, PEM, NRG, ESMO, Merck & Co., Webcast, Belzutifan, European Society for Medical Oncology, ADC, Research, TUC, KRAS, Lung cancer, RAS, AstraZeneca, EC, Adenocarcinoma, Head, TNBC, MRK, Pembrolizumab, Everolimus, CRC, Cancer, Olaparib, EFS, Quality of life (healthcare), SWOG, Congress, LBA32, LBA21, PBO, Chemoradiotherapy, CP, Safety, MBC, Patient, Pharmaceutical industry, Birth control, Medical imaging, Animal feed, Vaccine, Tras, Merck, NSCLC, Eisai

The event will take place virtually and will be accessible via webcast.

Key Points: 
  • The event will take place virtually and will be accessible via webcast.
  • Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC.
  • Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801.
  • mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response.

 Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer

Retrieved on: 
火曜日, 10月 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ENAD Ayiou Dometiou FC, Radiation, University, Therapy, Function, Bio, Cancer Research UK, University college, Research fellow, Antibody, Radiation therapy, Cancer Science, University of Glasgow, MRI, Date, Primary tumor, Transgene, Patient, Monochorionic twins, Master of Science, School, Chemokine, Cytokine, Society, Vaccine, Medical imaging, Safety, Chemoradiotherapy

In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.

Key Points: 
  • In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.
  • Further, hexon staining of patient samples suggested EnAd localization in both the primary tumor and in metastatic sites.
  • “These data are compelling given the higher-than-expected pCR/cCR rate, and the low adverse event rate highlights the ability to deliver the oncolytic virus concurrently with chemoradiation.
  • ET
    Presenter: Dr Séan M. O’Cathail, MSc DPhil MRCPI FRCP FRCR, Senior Research Fellow, School of Cancer Sciences, University of Glasgow

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

Retrieved on: 
月曜日, 10月 2, 2023
Vaccine, DNA, Biotechnology, University, FIGO, Nucleic acid thermodynamics, PDSB, Neoplasm, ASTRO, Infection, HPV16, Cancer, SOC, Monroe Dunaway Anderson, Radiation therapy, Doctor of Philosophy, MD Anderson Cancer Center, CD8, Cervical cancer, MD, Patient, Lymph, Blood, Annual general meeting, American Society for Radiation Oncology, HPV, Chemoradiotherapy, Gynaecology, Oncology, CRT, Kinetics, Society, Human papillomavirus infection, Disease, Birth control, Medical imaging, Obstetrics

HPV is the primary cause of cervical cancer with over 99% caused by HPV infection, and cfHPV-DNA can be detected in the blood of patients with cervical cancer.

Key Points: 
  • HPV is the primary cause of cervical cancer with over 99% caused by HPV infection, and cfHPV-DNA can be detected in the blood of patients with cervical cancer.
  • HPV type 16 (HPV16) is the most prominent subtype associated with cervical cancer.
  • Longitudinal plasma samples were collected from each patient at baseline, during weeks 1, 3, and 5, and at 3-4 months after CRT.
  • “I look forward to the continued evaluation of PDS0101 in combination with standard-of-care chemoradiotherapy.”

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Unveil Wide Range of Innovative Radiation Oncology Research at the 2023 ASTRO Annual Meeting

Retrieved on: 
金曜日, 9月 29, 2023
KRAS, Abstract, RWJBarnabas Health, ASTRO, Survival, NCI-designated Cancer Center, Cancer, National Cancer Institute, Radiation, Breast, Research, Radiation therapy, Lung cancer, Immunotherapy, Associate, Lung, MS, PDA, MRD, Cooper University Hospital, Patient, Standard of care, Annual general meeting, Chemoradiotherapy, Rutgers Cancer Institute of New Jersey, Radio, Society, American Society for Radiation Oncology, Methionine, Medical imaging, MD

NEW BRUNSWICK, N.J., Sept. 29, 2023 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present new, novel, and expansive radiation oncology data from their clinical research program at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting, to be held in San Diego from October 1-4.  A total of 10 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and use of radiation therapy in the treatment of lung, breast, pancreatic, and other cancers. Rutgers Cancer Institute and RWJBarnabas Health is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • Rutgers Cancer Institute and RWJBarnabas Health is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • "We are excited that the physician-scientists from our health system will be presenting significant and valuable information to advance the use of radiotherapy in cancer treatment at this year's ASTRO meeting," said Bruce Haffty, MD, MS, Chair, Radiation Oncology, Associate Vice Chancellor for Cancer Programs at Rutgers Cancer Institute of New Jersey, and System Director of Radiation Oncology at RWJBarnabas Health.
  • Highlights of accepted abstracts include the following:
    Findings of an analysis to explore genetic changes in aggressive pancreatic cancer.
  • The full list of presentations at this year's ASTRO Annual Meeting follows:

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
水曜日, 9月 20, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, MSD, Bevacizumab, Progression-free survival, Neoplasm, MRK, Immunotherapy, PFS, Merck & Co., HIV disease progression rates, Cervical cancer, Patient, CPS, Brachytherapy, PDUFA, EBRT, FDA, Chemoradiotherapy, Recurrence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PD-L1, NYSE, Food, Disease, Pharmaceutical industry, Merck

The sBLA is based on data from the KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, in which KEYTRUDA plus concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone.

Key Points: 
  • The sBLA is based on data from the KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, in which KEYTRUDA plus concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone.
  • If approved, this would be Merck’s third approved indication in cervical cancer and first in an earlier stage of the disease.
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of January 20, 2024.
  • “If approved, KEYTRUDA will be the first immunotherapy available for patients with newly diagnosed high-risk locally advanced cervical cancer.

Humanetics Corporation Publishes Positive Clinical Trial Results of BIO 300 in Patients with Non-Small Cell Lung Cancer

Retrieved on: 
火曜日, 9月 19, 2023
Contracts, Law Enforcement, Emergency Services, Pharmaceutical, Oncology, General Health, Defense, Seniors, Public Policy, Government, Men, Clinical Trials, Family, Science, Consumer, Health, Research, Tidal volume, BIO, Radiation, COVID-19, Survival, Clinical trial, Cancer, Quality of life, Pharmacokinetics, Toxicity, Lung cancer, Radiation therapy, Pulmonary fibrosis, Humanetics, Patient, Canadian International Council, Risk, Neoplasm, Pulmonary toxicity, Chemoradiotherapy, Human, Safety, Medical imaging, Pharmaceutical industry, NSCLC

A recently published paper in the International Journal of Radiation Oncology – Biology – Physics (Red Journal) details encouraging results from a multicenter clinical study conducted with Humanetics Corporation’s (Humanetics) novel radioprotective drug, BIO 300, in patients with non-small cell lung cancer (NSCLC).

Key Points: 
  • A recently published paper in the International Journal of Radiation Oncology – Biology – Physics (Red Journal) details encouraging results from a multicenter clinical study conducted with Humanetics Corporation’s (Humanetics) novel radioprotective drug, BIO 300, in patients with non-small cell lung cancer (NSCLC).
  • Twenty-one patients were enrolled in the phase 1b/2a study evaluating the safety and clinical utility of BIO 300 as a radioprotector of normal tissues in patients with NSCLC ( NCT02567799 ).
  • In addition, patients receiving BIO 300 had a lower rate of hematological, pulmonary, and gastrointestinal toxicities compared to previous clinical studies with the same chemoradiotherapy regimen in the absence of BIO 300.
  • BIO 300 is also under advanced development as a radiation medical countermeasure for the military and first responders, and BIO 300 is in a phase 2b trial evaluating the clinical utility of BIO 300 to protect lung tissues against the long-term effects of COVID-19 ( NCT04482595 ).

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
水曜日, 7月 19, 2023
Women, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Oncology, MSD, Bevacizumab, Obstetrics, Progression-free survival, Catholic higher education, OS, MRK, Research, PFS, Merck & Co., HIV disease progression rates, Cervical cancer, Patient, CPS, Brachytherapy, EBRT, Gynaecology, GOG, Data monitoring committee, Chemoradiotherapy, Recurrence, PD-L1, NYSE, Disease, Pharmaceutical industry, Merck

A favorable trend in overall survival (OS), the trial’s other primary endpoint, was also observed for KEYTRUDA plus concurrent chemoradiotherapy compared to concurrent chemoradiotherapy alone; however, these OS data were not mature at the time of this interim analysis.

Key Points: 
  • A favorable trend in overall survival (OS), the trial’s other primary endpoint, was also observed for KEYTRUDA plus concurrent chemoradiotherapy compared to concurrent chemoradiotherapy alone; however, these OS data were not mature at the time of this interim analysis.
  • The trial is continuing and follow-up of OS is ongoing.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • “We are encouraged by these results that show treatment with KEYTRUDA significantly improved progression-free survival for patients with newly diagnosed high-risk locally advanced cervical cancer.

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

Retrieved on: 
木曜日, 6月 29, 2023
Carcinoma, Progression-free survival, Survival, Lung cancer, Cancer, Cardiac resynchronization therapy, Prognosis, SOC, NSCLC, Trial of the century, Global Research, SCLC, BTLA, Junshi, SSE, Development, HIV disease progression rates, Patient, Standard of care, Mortality, Hospital, MOS, Chemoradiotherapy, CRT, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Safety, Small-cell carcinoma, Pharmaceutical industry

According to GLOBOCAN 2020, lung cancer is a form of malignant tumor with the highest incidence rate and mortality in China.

Key Points: 
  • According to GLOBOCAN 2020, lung cancer is a form of malignant tumor with the highest incidence rate and mortality in China.
  • Lung cancer can be broadly categorized into non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”), based on cell type.
  • Specifically, small cell lung cancer is the most invasive subtype of lung cancer, accounting for about 15%-20% of all lung cancer cases with characteristics such as rapid progression, early metastasis, and poor prognosis.
  • Small cell lung cancer includes limited-stage small cell lung cancer (“LS-SCLC”) and extensive-stage small cell lung cancer, and LS-SCLC accounts for about one-third of all small cell lung cancer cases.

Lunit and the Japan National Cancer Center Hospital East Partner in AI Pathology to Advance Precision Oncology

Retrieved on: 
火曜日, 5月 30, 2023
Partnership, TIL, HER2, MSS, American Society of Clinical Oncology, Pathology, Cancer, Biomarker, H&E, PCR, Immunohistochemistry, ASCO, LARC, Patient, TME, AI, SCRUM, Chemoradiotherapy, CRT, Tumor microenvironment, PD-L1, Society, Medical device, Medical imaging

SEOUL, South Korea, May 30, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer diagnostic solutions, today announced collaboration with the National Cancer Center Hospital East (NCCHE) to evaluate and validate its AI pathology solution for tissue data analysis.

Key Points: 
  • SEOUL, South Korea, May 30, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer diagnostic solutions, today announced collaboration with the National Cancer Center Hospital East (NCCHE) to evaluate and validate its AI pathology solution for tissue data analysis.
  • Working with Lunit and the SCRUM project will bring a new approach to cancer treatment," said the principal investigator of SCRUM-Japan MONSTAR-SCREEN project, Dr. Takayuki Yoshino of the National Cancer Center Hospital East (Kashiwa City, Chiba Prefecture).
  • Lunit and NCCHE remain committed to conducting studies to further validate the findings and to explore AI analysis in additional treatment settings.
  • "We are delighted to partner with the National Cancer Center Hospital East in the validation of our Lunit SCOPE suite, marking a significant step towards advancing precision oncology and improving optimized patient treatment," said Brandon Suh, CEO of Lunit.